Yellow fever vaccine, Institut Pasteur

BIOLOGICAL2 trials

Sponsors

Epicentre, University of Oxford

Conditions

Yellow Fever

Phase 4

Immunogenicity and Safety of Fractional Doses of Yellow Fever Vaccines (YEFE)

CompletedNCT02991495

EpicentreYellow Fever

Start: 2017-11-06End: 2021-12-31Updated: 2022-02-01

Non- Inferiority Fractional-doses Trial for Yellow Fever Vaccine

CompletedNCT04059471

University of OxfordYellow Fever

Start: 2019-11-11End: 2023-06-24Updated: 2024-02-09

Related Papers

Low-dose yellow fever vaccination in infants: a randomised, double-blind, non-inferiority trial.

2026-01-13

Low-Dose Yellow Fever Vaccine in Adults in Africa

New England Journal of Medicine2025-02-1911 citations

Immunogenicity and safety of fractional doses of 17D-213 yellow fever vaccine in children (YEFE): a randomised, double-blind, non-inferiority substudy of a phase 4 trial.

2023-04-2811 citations

Immunogenicity and safety of fractional doses of 17D-213 yellow fever vaccine in HIV-infected people in Kenya (YEFE): a randomised, double-blind, non-inferiority substudy of a phase 4 trial.

2023-04-288 citations

Immunogenicity and safety of fractional doses of yellow fever vaccines: a randomised, double-blind, non-inferiority trial.

2021-01-0142 citations

Randomized, double-blinded, controlled non-inferiority trials evaluating the immunogenicity and safety of fractional doses of Yellow Fever vaccines in Kenya and Uganda.

2019-11-2011 citations